Nada A Al-Hasawi,Ladislav Novotny
Nada A Al-Hasawi
Background/aim: This review surveys scientific literature published mainly during the past five years to compile information on the anti-glioma activities of various flavonoid groups, with particular attention to structur...
Prognostic Impact of Claudin18.2 and TROP2 Expression in Advanced Gastric Cancer Treated With Nivolumab [0.03%]
Claudin18.2和TROP2表达对纳武利尤单抗治疗晚期胃癌预后影响的研究
Takahito Awatsu,Toru Kadono,Hirokazu Shoji et al.
Takahito Awatsu et al.
Background/aim: The combination of chemotherapy and nivolumab has become the standard first-line therapy for advanced gastric cancer (AGC) following the results of the CheckMate 649 and ATTRACTION-4 trials. Claudin18.2 (C...
Delayed Initiation of S-1 Adjuvant Chemotherapy Impairs Survival in Patients With Curatively Resected Pancreatic Cancer [0.03%]
胰腺癌手术治愈患者的S-1辅助化疗的延迟启动损害了患者的生存率
Dongha Lee,Hirochika Toyama,Yoshihide Nanno et al.
Dongha Lee et al.
Background/aim: The prognostic impact of the timing of adjuvant chemotherapy initiation in patients with resected pancreatic cancer is unclear. Therefore, this study aimed to investigate whether delayed initiation of S-1 ...
Oncogenic Role and Clinical Significance of NPM1 in Colorectal Cancer via the AKT/mTOR Signaling Pathway [0.03%]
NPM1在结直肠癌中的致癌作用及其临床意义：通过AKT/mTOR信号通路研究
Hong-Beum Kim,Hee-Jeong Lee,Sang-Gon Park
Hong-Beum Kim
Background/aim: Colorectal cancer (CRC) remains a major global health challenge with poor survival in advanced disease. Identifying new oncogenic drivers is essential for improving diagnosis and therapy. This study invest...
Clinicopathologic Predictors of Outcome and Implications for Adjuvant Therapy in Pathologic Stage II Non-small Cell Lung Cancer [0.03%]
病理分期Ⅱ期非小细胞肺癌预后影响因素的临床病理分析及辅助治疗的指征研究
Yi-Wen Shen,Tai-Huang Lee,Hui-Yang Hung et al.
Yi-Wen Shen et al.
Background/aim: Pathologic stage II non-small cell lung cancer (NSCLC) exhibits heterogeneous outcomes despite curative resection. Although adjuvant EGFR-TKI and immunotherapy have improved survival in resected NSCLC, sub...
Synergistic Effects of Honokiol on Camptothecin-triggered Apoptosis of Drug-resistant Glioblastoma Cells via CDK1-mediated G2/M Arrest and Intrinsic ROS-Mitochondrion-dependent Pathway [0.03%]
Honokiol协同促进鬼臼毒素诱导的耐药胶质母细胞瘤细胞凋亡的作用机制研究：通过CDK1介导的G2/M阻滞和内在ROS-线粒体依赖性途径
Chih-Pin Yang,Jui-Tai Chen,Shing-Hwa Liu et al.
Chih-Pin Yang et al.
Background/aim: Temozolomide (TMZ) is the first-line drug for the treatment of glioblastoma multiforme (GBM). Unfortunately, most patients with GBM eventually develop drug resistance. Camptothecin (CPT) and honokiol (HNK)...
Lenvatinib Exhibits Potent Anti-tumor Activity and Favorable Safety Profile in a Colorectal Cancer Xenograft Model [0.03%]
仑伐替尼在结直肠癌异种移植瘤模型中表现出显著的抗肿瘤作用和良好的安全性
Chen-Yu Kuo,Tsai-Lan Liao,Fei-Ting Hsu et al.
Chen-Yu Kuo et al.
Background/aim: Lenvatinib, a multikinase inhibitor, has shown potential anti-tumor activity in various cancers. This study evaluated its efficacy, safety, and apoptotic mechanisms in colorectal cancer (CRC) using HT-29 x...
Prognostic Significance of Extrapancreatic Invasion in Pancreatic Cancer: Excellent Outcomes in Patients With Disease Confined Within the Pancreas [0.03%]
胰腺癌预后的影响：胰腺内肿瘤的临床病理特征及良好预后的意义
Ryo Saito,Hidetake Amemiya,Wataru Izumo et al.
Ryo Saito et al.
Background/aim: Extrapancreatic invasion (EPI) is a well-known adverse prognostic factor in pancreatic cancer; however, whether the absence of EPI defines a distinct clinical entity remains unclear. This study aimed to cl...
Qudus Kolawole,Veera L D Badisa,Musiliyu A Musa et al.
Qudus Kolawole et al.
Background/aim: Coumarins (Benzopyran-2-one) are a broad class of compounds of both natural and synthetic origin with diverse pharmacological properties that have attracted intense interest in recent years. For example, t...
Treatment Patterns and Prognostic Factors of Anti-HER2 Therapy in HER2-positive Advanced/Recurrent Gastric Cancer [0.03%]
赫二阳性晚期/复发胃癌抗赫二治疗模式及预后因素分析
Noriko Wada,Yukinori Kurokawa,Tsuyoshi Takahashi et al.
Noriko Wada et al.
Background/aim: Human epidermal growth factor receptor 2 (HER2) over-expression occurs in approximately 10-20% of gastric cancers. While HER2-positive tumors tend to behave more aggressively, anti-HER2 therapy has markedl...